BACKGROUND: No retrievable and repositionable second generation transcatheter aortic valve is available in China. Here, we report the first-in-man implantation of the retrievable and repositionable VenusA-Plus valve.
INTRODUCTION
Transcatheter aortic valve replacement (TAVR) is a safe and effective alternative treatment to surgical aortic valve replacement (SAVR) for patients with symptomatic severe aortic stenosis (AS) who are at increased surgical risk (STS or EuroSCORE II≥4% or logistic EuroSCORE I≥10%). [1] In patients who received first generation devices, bicuspid AS had more frequent moderate-to-severe PVL especially with the self-expanding device. 2 However, in China, patients presenting for TAVR have a significantly higher frequency of bicuspid valve morphology and more severe leaflets calcifi cation. [3, 4] Although VenusA-valve (Venus Medtech Inc., Hangzhou, China) was approved by the China Food and Drug Administration (CFDA) as the first domestic self-expanding transcatheter heart valve (THV), Chinese patients needed the second generation THV with the ability to retrieve and reposition especially in cases of unfavorable anatomies such as bicuspid AS and heavily calcifi cation.
VenusA-Plus valve (Venus Medtech Inc., Hangzhou, China) is built upon the VenusA-Valve and is the second generation THV with an improved and reinforced shaft and capsule allowing for retrievability and repositionability. Herein, we described the first-in-man World J Emerg Med, Vol 9, No 1, 2018 implantation with this new device in a bicuspid AS patient.
CASE
A 76-year-old lady referred to our hospital due to symptomatic severe aortic stenosis with aortic valve area of 0.55 cm 2 , mean pressure gradient of 46 mmHg and maximum velocity of 4.42 m/s. With the comorbidities of coronary artery disease, hypertension, type 2 diabetes mellitus, history of right lower extremity amputation due to bone tumor and NYHA functional class IV, the STS score was calculated as 13.8%. The heart valve team recommended TAVR. Pre-TAVR dual source computed tomography evaluation showed type 0 bicuspid aortic valve with asymmetric calcification. The unfavorable anatomies increase the possibility of malposition and paravalvular leakage during TAVR using the first generation of self-expanding valve, such as CoreValve (Medtronic, Minneapolis, MN, USA) and Venus A valve. The second generation retrievable and repositionable VenusA-Plus valve was preferred in this unfavorable situation and ethical permission was obtained from the hospital. With the 21.2 mm in diameter annulus ( Figure  1A ) and asymmetric calcified leaflets ( Figure 1B) , a 26 mm VenusA-Plus ( Figure 1C ) valve was selected. The TAVR procedure was performed through transfemoral access under local anesthesia with sedation on November 23, 2017. Pre-dilation with a 20-mm Z-MED balloon (NuMED, Inc., Hopkinton, New York) was performed before the VenusA-Plus valve was implanted. The valve was then successfully crossed through the aortic arch and implanted in an ideal position without second attempt. The pressure gradient dropped from 44 mmHg to 0 mmHg with trivial paravalvular leak ( Figure 1D ).
Pre-discharge TTE revealed an aortic valve area of 1.35 mm 2 , mean pressure gradient of 5 mmHg and maximum velocity of 1.6 m/s. The patient's NYHA functional class was improved to class III without stroke and new pacemaker implantation.
DISCUSSION
The TAVR situation in China is in its infancy with a very limited number of cases. The aortic root anatomies of TAVR candidates are much more complicated than those in western countries. [3, 4] Therefore, the need of new generation retrievable and repositionable THV is urgent in China.
VenusA-valve is the fi rst approved THV by CFDA with a similar design to the CoreValve but a stronger radial force designed for bicuspid aortic valve and severe calcifi cation. However, the fi rst generation VenusA valve system is not retrievable and repositionable. It is very challenging to have a retrievable delivery system for the higher expansion force VenusA-Valve. The VenusA-Plus retrievable delivery system has the same profi le and working length as the current Venus-A delivery catheter. However, its shaft and capsule are reinforced with wire mesh to have enough pushability while maintain its fl exibility ( Figure 1E and F) .
The successful fi rst-in-man implantation indicates that the retrievable and repositionable VenusA-Plus valve is feasible in complicated TAVR cases such as bicuspid aortic valve. Future multi-center clinical trials are necessary before the new device will be widely used.
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